DETECT V/CHEVENDO - Comparison of dual HER2-targeted therapy with trastuzumab plus pertuzumab in combination with chemo- or endocrine therapy in addition with CDK4/6 inhibition in patients with HER2-positive and hormone-receptor positive metastatic breast cancer

被引：2
|
作者：
Krause, S.
Friedl, T.
Fehm, T.
Romashova, T.
Fasching, P. A.
Schneeweiss, A.
Mueller, V.
Taran, F-A
Polasik, A.
Tzschaschel, M.
De Gregorio, A.
Meier-Stiegen, F.
Janni, W.
Huober, J.
机构：
[1] Univ Hosp Ulm, Ulm, Germany
[2] Heinrich Heine Univ Dusseldorf, Dusseldorf, Germany
[3] Univ Hosp Erlangen, Erlangen, Germany
[4] Natl Ctr Tumor Dis, Heidelberg, Germany
[5] Univ Hosp Heidelberg, Heidelberg, Germany
[6] Univ Hosp Hamburg Eppendorf, Hamburg, Germany
[7] Univ Hosp Tubingen, Tubingen, Germany
来源：
CANCER RESEARCH | 2019年 / 79卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS18-OT2-07-01
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OT2-07-01
引用
收藏
页数：3
相关论文
共 50 条
  • [1] DETECT V - Comparison of dual HER2-targeted therapy with trastuzumab and pertuzumab plus CDK4/6 inhibition in combination with either chemo- or endocrine therapy in patients with HER2-positive and hormone-receptor positive metastatic breast cancer
    Friedl, Thomas W. P.
    Krause, Sabrina
    Fehm, Tanja
    Fasching, Peter A.
    Schneeweiss, Andreas
    Mueller, Volkmar
    Riethdorf, Sabine
    Pantel, Klaus
    Taran, Florin-Andrei
    Polasik, Arkadius
    Tzschaschel, Marie
    de Gregorio, Amelie
    Meier-Stiegen, Franziska
    Janni, Wolfgang
    Huober, Jens
    CANCER RESEARCH, 2020, 80 (04)
  • [2] The DETECT V-Study - Comparison of dual HER2-targeted therapy with Trastuzumab plus Pertuzumab in combination with Chemo- or Endocrine Therapy in Addition with CDK4/6 Inhibition in Patients with HER2-positive and Hormone-receptor positive Metastatic Breast Cancer
    Romashova, T.
    Polasik, A.
    Friedl, T. W. P.
    Rack, B.
    Tzschaschel, M.
    Fasching, P. A.
    Taran, F. -A.
    Hartkopf, A.
    Schneeweiss, A.
    Mueller, V.
    Aktas, B.
    Pantel, K.
    Meier-Stiegen, F.
    Wimberger, P.
    Janni, W.
    Fehm, T.
    Huober, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 33 - 33
  • [3] The DETECT V-Study - Comparison of dual HER2-targeted therapy with trastuzumab plus pertuzumab in combination with chemo-or endocrine therapy in addition with CDK4/6 inhibition in patients with HER2-positive and hormone-receptor positive metastatic breast cancer
    Romashova, Tatiana
    Polasik, Arkadius
    Friedl, Thomas W. P.
    Rack, Brigitte
    Tzschaschel, Marie
    Fasching, Peter A.
    Taran, Florin-Andrei
    Hartkopf, Andreas
    Schneeweiss, Andreas
    Mueller, Volkmar
    Bahriye, Aktas
    Pantel, Klaus
    Meier-Stiegen, Franziska
    Wimberger, Pauline
    Janni, Wolfgang
    Fehm, Tanja
    Huober, Jens
    CANCER RESEARCH, 2018, 78 (04)
  • [4] The DETECT V-study - Comparison of dual HER2-targeted therapy with trastuzumab plus pertuzumab in combination with chemo-or endocrine therapy in patients with HER2-positive and hormone-receptor positive metastatic breast cancer
    Polasik, A.
    Schramm, A.
    Friedl, T. W. P.
    Rack, B.
    Trapp, E.
    Tzschaschel, M.
    Fasching, P. A.
    Taran, F-A
    Hartkopf, A.
    Schneeweiss, A.
    Mueller, V.
    Aktas, B.
    Pantel, K.
    Meier-Stiegen, F.
    Wimberger, P.
    Janni, W.
    Fehm, T.
    CANCER RESEARCH, 2017, 77
  • [5] Toxicity of chemo- versus endocrine therapy in combination with dual HER2-targeted therapy with trastuzumab and pertuzumab plus ribociclib in patients with HER2 positive and hormone-receptor positive metastatic breast cancer - results from an Interim Safety Analysis of DETECT V
    Schochter, Fabienne
    Huober, Jens
    Fehm, Tanja
    Mueller, Volkmar
    Rack, Brigitte
    Just, Marianne
    Sagasser, Jacqueline
    Schmidt, Marcus
    Decker, Thomas
    Hartkopf, Andreas
    Schneeweiss, Andreas
    Friedl, Thomas W. P.
    Janni, Wolfgang
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 26 - 26
  • [6] Pertuzumab: A New Targeted Therapy for HER2-Positive Metastatic Breast Cancer
    Malenfant, Stephanie J.
    Eckmann, Karen R.
    Barnett, Chad M.
    PHARMACOTHERAPY, 2014, 34 (01): : 60 - 71
  • [7] Impact of adjuvant trastuzumab on outcomes of HER2-positive breast cancer patients treated with HER2-targeted therapy in the metastatic setting
    Murthy, Rashmi Krishna
    Varma, Ankur
    Mishra, Priyankana
    Hess, Kenneth R.
    Young, Elliana J.
    Murray, James L.
    Koenig, Kimberly Higginbotham
    Green, Marjorie C.
    Moulder, Stacy L.
    Melhem-Bertrandt, Amal
    Booser, Daniel J.
    Valero, Vicente
    Hortobagyi, Gabriel N.
    Esteva, Francisco J.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [8] Efficacy of HER2-targeted therapy for patients with HER2-positive breast cancer according to hormone receptor status.
    Murata, Takeshi
    Takahashi, Maiko
    Hayashida, Tetsu
    Jinno, Hiromitsu
    Kitagawa, Yuko
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (26)
  • [9] CDK4/6 inhibition in HER2-positive breast cancer Comment
    Battisti, Nicolo Matteo Luca
    Ring, Alistair
    LANCET ONCOLOGY, 2020, 21 (06): : 734 - 735
  • [10] Takotsubo Syndrome during Pertuzumab and Trastuzumab Therapy for HER2-Positive Metastatic Breast Cancer
    Irelli, Azzurra
    Ceriello, Laura
    Patruno, Leonardo Valerio
    Tessitore, Alessandra
    Alesse, Edoardo
    Cannita, Katia
    Fabiani, Donatello
    BIOMEDICINES, 2024, 12 (01)
12345